Journal
PHARMACOGENOMICS
Volume 10, Issue 3, Pages 339-344Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/14622416.10.3.339
Keywords
genetic variant; inhibitor; OATP1A2; pharmacogenetics; SLCO1A2; SNP; substrate; transporter
Categories
Funding
- US Public Health Service Cancer Center Support [3P30CA021765]
- American Lebanese Syrian Associated Charities (ALSAC)
Ask authors/readers for more resources
The solute carrier, human organic anion transporting polypeptide 1A2 (OATP1A2, OATP-A, OATP1 and OATP) is highly expressed in the intestine, kidney, cholangiocytes and the blood-brain barrier. This localization suggests that OATP1A2 may be vitally important in the absorption, distribution and excretion of a broad array of clinically important drugs. Several nonsynonymous polymorphisms have been identified in the gene encoding OATP1A2, SLCO1A2 (SLC21A3), with some of these variants demonstrating functional changes in the transport of OATP1A2 substrates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
